Your browser doesn't support javascript.
loading
The Lineage Determining Factor GRHL2 Collaborates with FOXA1 to Establish a Targetable Pathway in Endocrine Therapy-Resistant Breast Cancer.
Cocce, Kimberly J; Jasper, Jeff S; Desautels, Taylor K; Everett, Logan; Wardell, Suzanne; Westerling, Thomas; Baldi, Robert; Wright, Tricia M; Tavares, Kendall; Yllanes, Alex; Bae, Yeeun; Blitzer, Jeremy T; Logsdon, Craig; Rakiec, Daniel P; Ruddy, David A; Jiang, Tiancong; Broadwater, Gloria; Hyslop, Terry; Hall, Allison; Laine, Muriel; Phung, Linda; Greene, Geoffrey L; Martin, Lesley-Ann; Pancholi, Sunil; Dowsett, Mitch; Detre, Simone; Marks, Jeffrey R; Crawford, Gregory E; Brown, Myles; Norris, John D; Chang, Ching-Yi; McDonnell, Donald P.
Afiliação
  • Cocce KJ; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA.
  • Jasper JS; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA.
  • Desautels TK; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA.
  • Everett L; Department of Biological Sciences, North Carolina State University, Raleigh, NC 27695, USA.
  • Wardell S; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA.
  • Westerling T; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
  • Baldi R; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA.
  • Wright TM; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA.
  • Tavares K; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA.
  • Yllanes A; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA.
  • Bae Y; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA.
  • Blitzer JT; Viba Therapeutics, San Francisco, CA 94158, USA.
  • Logsdon C; Department of Cancer Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
  • Rakiec DP; Novartis Institutes for Biomedical Research, Oncology Disease Area, Cambridge, MA 02139, USA.
  • Ruddy DA; Novartis Institutes for Biomedical Research, Oncology Disease Area, Cambridge, MA 02139, USA.
  • Jiang T; Department of Biostatistics, Duke Cancer Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Broadwater G; Department of Biostatistics, Duke Cancer Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Hyslop T; Department of Biostatistics, Duke Cancer Institute, Duke University School of Medicine, Durham, NC 27710, USA.
  • Hall A; Department of Pathology, Duke University School of Medicine, Durham, NC 27710, USA.
  • Laine M; The Ben May Department for Cancer Research, The University of Chicago, Chicago, IL 60637, USA.
  • Phung L; The Ben May Department for Cancer Research, The University of Chicago, Chicago, IL 60637, USA.
  • Greene GL; The Ben May Department for Cancer Research, The University of Chicago, Chicago, IL 60637, USA.
  • Martin LA; Breast Cancer Now, Toby Robins Research Centre, Institute of Cancer Research, London, SW3 6JB, UK.
  • Pancholi S; Breast Cancer Now, Toby Robins Research Centre, Institute of Cancer Research, London, SW3 6JB, UK.
  • Dowsett M; Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital NHS Trust, London, SW3 6JJ, UK.
  • Detre S; Ralph Lauren Centre for Breast Cancer Research, Royal Marsden Hospital NHS Trust, London, SW3 6JJ, UK.
  • Marks JR; Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.
  • Crawford GE; Department of Pediatrics, Duke University School of Medicine, Durham, NC 27710, USA.
  • Brown M; Center for Functional Cancer Epigenetics, Dana-Farber Cancer Institute, Boston, MA 02215, USA; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA 02215, USA.
  • Norris JD; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA.
  • Chang CY; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA.
  • McDonnell DP; Department of Pharmacology and Cancer Biology, Duke University School of Medicine, Durham, NC 27710, USA. Electronic address: donald.mcdonnell@duke.edu.
Cell Rep ; 29(4): 889-903.e10, 2019 10 22.
Article em En | MEDLINE | ID: mdl-31644911
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fatores de Transcrição / Fator 3-alfa Nuclear de Hepatócito / Neoplasias Mamárias Experimentais Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Cell Rep Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fatores de Transcrição / Fator 3-alfa Nuclear de Hepatócito / Neoplasias Mamárias Experimentais Tipo de estudo: Prognostic_studies Limite: Animals / Female / Humans Idioma: En Revista: Cell Rep Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Estados Unidos